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Background: Long-term functional schizophrenia outcomes are not well
characterized in low-income environments because of the rarity of prospective
studies.
Objectives: To assess and describe long-term schizophrenia’s functional outcomes
and potential outcome predictors.
Methods: Following a baseline assessment, 316 people with schizophrenia were
studied for 10 years, on average. Of the total, 79 were incident cases: cases with
onset of the illness occurring two years or less from entry into the study. SF-36
scores of physical and social functioning were used to assess functional.e01272
vier Ltd. This is an open access article under the CC BY-NC-ND license
y-nc-nd/4.0/).
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functioning with potential predictors.
Results: Social and physical functioning scores regarding the cohort were lower
than the population’s norm for most of the follow-up period. Incident cases had
better function than prevalent cases. Fifteen percent of incident and 30% of
prevalent cases had reduced social functioning for at least six years. Declining
symptom severity during the follow-up period was signiﬁcantly associated with
improvement in social functioning. When baseline functioning was controlled
for, the long-term trend in functionality was not associated with demographic or
illness characteristics (age and speed of onset, duration of illness and neuroleptic
use at entry, substance use, and medication adherence).
Conclusion: Long-term physical and social functioning of the population with
schizophrenia were signiﬁcantly lower than the population norm. A signiﬁcant
proportion of the cohort had lower functioning for the long-term. Functioning was
not associated with demographic or illness characteristics of the study population.
Keywords: Psychiatry, Clinical psychology, Epidemiology, Public health
1. Introduction
The ﬁeld of mental health services has experienced a shift from its previous
emphasis to reduce symptoms through a treatment focused approach to taking
into consideration both the functioning and well-being of the patient (Brazier
et al., 2014). Follow-up studies of schizophrenia have often focused on clinical out-
comes, with less consideration of functional outcomes (Feeny et al., 2013). In those
studies that examined functional outcomes the measuring instruments used were not
generic and or they lack data on population norms, and thus comparison of the
disability of schizophrenia to the general population or other illness was not possible.
Prospective population-based studies of course and outcome of schizophrenia are
scarce in low and middle-income countries. Of these, studies focusing on physical
and social functioning are even rarer (Ran et al., 2017; Esan et al., 2012; Novick
et al., 2012; Gureje and Cohen, 2011; Thara et al., 1994; Ohaeri, 1993). We have
earlier reported on short-term functional outcomes, and long-term clinical course
and outcome of schizophrenia in Butajira, a rural community in Ethiopia (Shibre
et al., 2014; Alem et al., 2009; Kebede et al., 2004a).
The unique features of the study were that cases were recruited from the community
instead of clinics, and over three-quarters of these were neuroleptic naïve at entry.
Also, we used the Medical Outcomes Short Form (SF-36) instrument a generic func-
tional assessment instrument that enables comparison with the population norm or
other illnesses. Because of the availability of published local general population normson.2019.e01272
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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functioning of the people with schizophrenia to the general population of Butajira.
In this paper, we describe the long-term social and physical functional outcome of
people with schizophrenia that were followed for an average of 10 years. We also
present the results of comparisons of functioning between our cohort with
general population of Butajira. Also, we have evaluated several potential socio-
demographic and clinical predictors of physical and social functioning in
schizophrenia.2. Methods
Details concerning case identiﬁcation methods for Butajira’s cohort have been pre-
viously reported (Shibre et al., 2014; Shibre et al., 2002; Kebede et al., 2003; Alem
et al., 2009) and are as follows:
Butajira is a predominantly rural district, located in central Ethiopia and found
approximately 132 km from the capital, Addis Ababa. Primary occupations in this
area include farming, as well as small businesses which are located in town.
Participants were enrolled into the study between March 1998 and May 2001,
following a two-stage method. Throughout the initial stage, 68,378 adults, aged
15e49 years (out of the total district population of the age group of 83,282) were in-
terviewed via home surveys which used the Composite International Diagnostic Inter-
view (CIDI 2.1) (Sartorius and Janca, 1996; Ust€un et al., 1997). The key informant
method was used to identify and recruit additional participants (Shibre et al., 2002).
Participants found positive during this stage were given a diagnostic assessment using
Schedules for Clinical Assessment in Neuropsychiatry (SCAN 2.1) (Sartorius and
Janca, 1996; Ust€un et al., 1997). Following SCAN interviews, 359 persons conﬁrmed
to have schizophrenia (APA, 1994;World Health Organization, 1994), were placed in
the cohort of which, 46 cases with incomplete income data were excluded. This gave a
total of 316 cases, of which 79 were incident cases: cases with onset of the illness
occurring two years or less from entry into the study (Fig. 1). The study also identiﬁed
345 people with bipolar disorders and 215 with major depression. The relatively small
number of cases of major depression is because the screening process focused on iden-
tifying those people with major depression with psychotic features.
All participants were provided with access to basic psychiatric treatment, primarily
via ﬁrst-generation antipsychotics such as haloperidol, chlorpromazine, thiorida-
zine and ﬂuphenazine decanoate, as well as tricyclic antidepressants such as
amitriptyline or imipramine. These are commonly used in psychiatric clinics
throughout the country. Doses of antipsychotic medications and chlorpromazine
doses equivelant to the antipsychotic medications were provided at between 25
mg and 300 mg/day.on.2019.e01272
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 1. Flow diagram of the follow-up study of people with schizophrenia in Butajira, Ethiopia. *Inci-
dent cases with onset of illness two years or less at entry to the study.
4 https://doi.org/10.1016/j.heliy
2405-8440/ 2019 Published
(http://creativecommons.org/li
Article Nowe01272The primary outcomes that were evaluated yielded annual SF-36 scores on physical
and social functions: PF and SF. Follow-up measurements of clinical and functional
characteristics continued on a monthly basis in the Butajira psychiatric clinic, as well
as two additional outreach clinics established due to the research project.
The SF-36 scores were used to quantify functional outcomes. The SF-36 is often used
to measure functional outcomes regarding that of physical and mental illnesses, and
has proven to be eﬀective in measuring functioning, as well as health-related quality
of life (Brazier et al., 1992). The instrument continuously demonstrated appropriate
internal consistency and stability, aswell as concurrent validity in patients with schizo-
phrenia (Tunis et al., 1999; Russo et al., 1998). The Amharic version used here also
demonstrated reliability and validity in assessing Butajira’s general population
(Kebede et al., 2004b). The SF-36 instrument provides 36 items yielding eight do-
mains when scored. The initial domain includes physical functioning, which provides
an assessment of limitations to physical activities, such as walking and climbing. So-
cial functioning domain includes two items and examines impacts on physical andon.2019.e01272
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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domains to assess physical and social functioning because they directly assess daily
functions (Ware, 1993). Higher SF-36 scores represent higher function capabilities.
Clinical course, as well as outcome data were collected via the Longitudinal Interval
Follow-up Evaluation (LIFE) chart (Keller et al., 1987). The LIFE chart is a ques-
tionnaire able to summarize longitudinal data. Four psychiatrists were trained for
four days to administer and address the LIFE chart. Primary rating policies regarding
the LIFE chart include the Psychiatric Status Rating (PSR). The PSR is a six-point
symptom rating severity. A one rating indicates the absence of symptoms. In
contrast, a six rating is consistent with signiﬁcant or severe symptoms. Utilizing
all available information, the PSR provided reports from cases and families of those
experiencing the condition, monthly clinical records, annual symptomatic and func-
tional ratings, psychiatric nurse reports, and ﬁnally project outreach reports provided
by workers who held monthly contacts with patients and their families. When par-
ticipants were unable to attend the required psychiatric clinic for a ﬁnal assessment,
raters visited participants at home with their permission. Two senior psychiatrists
well-versed with the LIFE chart supervised ratings.
The Statistical Package for Social Sciences (SPSS version 19) and A SAS-based SF-
36 scoring algorithmwere used to analyze data. When comparing cohort SF-36 scores
to the general population, published SF-36 values of Butajira’s general population
were reviewed and used (Kebede et al., 2004b). In order to evaluate potential outcome
predictors linear mixedmodels on SPSS were used. Baseline values of outcomes were
included in the models to adjust for baseline diﬀerences in scores. Models for each
outcome were assessed, which were the yearly scores of PF and SF and PSR. The
following predictors were evaluated as predictors using the nine categorical variables:
age, sex, literacy, marital status, urban-rural residence, substance use, speed of onset,
neuroleptic use at baseline, and medication adherence. Seven continuous variables,
those being baseline PF, SF and PSR scores, follow-up PSR scores, age of onset, dura-
tion of illness at baseline, and duration of follow-up were also used. We ﬁtted multi-
variate random mixed linear models to evaluate long-term outcome (Twisk, 2003).2.1. Ethical considerations
Addis Ababa University’s Research and Publication Oﬃce approved the study. All
subjects or caregivers provided consent. Free health care, including medications,
were available to all participants throughout the follow-up.3. Results
A total of 316 people with schizophrenia that were identiﬁed at baseline and with
complete data on functional outcome were used in the analysis (Fig. 1), 79 of whichon.2019.e01272
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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Males accounted for 83% of cases in both the incident and prevalent cases (Table 1).
About three-quarters of the cohort were not married, living in rural areas. The
average age of incident cases (26 years) was lower than that of prevalent cases
(32 years). However, the average years of education were similar in the two groups
(about three years). At baseline, 75% of incident and 88% of prevalent cases had noTable 1. Baseline characteristics of people with schizophrenia in the Butajira
follow-up study, Ethiopia.
Incident Casesa Prevalent Cases All Cases
Number Percent Number Percent Number Percent
Sex Female 13 16.5 41 17.3 54 17.1
Male 66 83.5 196 82.7 262 82.9
Marital status Married 19 24.4 67 29.0 86 27.8
Others 59 75.6 164 71.0 223 72.2
Residence Urban 22 27.8 53 22.4 75 23.7
Rural 57 72.2 184 77.6 241 76.3
Speed of onset Acuteb 45 66.2 117 60.0 162 61.6
Insidious 23 33.8 78 40.0 101 38.4
History of treatment None 54 74.0 178 88.6 232 84.7
Other 19 26.0 23 11.4 42 15.3
Substance use No 60 75.9 144 60.8 204 64.6
Yes 19 24.1 93 39.2 112 35.4
Medication adherence 75% 49 62.0 144 60.8 193 61.1
>75% 30 38.0 93 39.2 123 38.9
Totalc 79 100.0 237 100.0 316 100.0
Mean Standard
Error (SE)
Mean SE Mean SE
Age Years 26.0 .8 32.2 .5 30.6 .5
Education Years 3.6 .5 2.8 .3 3.0 .2
Age of onset Years 24.9 .8 23.3 .5 23.7 .4
Follow-up duration Years 10.0 .3 10.6 .2 10.5 .2
Duration of illness
at entry to study
Years 1.4 .3 9.8 .6 7.6 .5
Baseline physical
functioning scored
Scale: 1-100 69.1 2.5 58.4 1.6 61.0 1.4
Baseline social
functioning scored
Scale: 1-100 48.7 2.8 40.4 1.3 42.5 1.2
Baseline symptom
severity scoree
Scale: 1-6 5.2 .1 4.9 .1 4.9 .1
a Incident cases are those with the onset of illness two years or less on entry to the study.
b Acute ¼ onset within three months or less.
cMissing values not shown-sub-totals may vary.
d Higher mean score values indicate higher functioning.
e Higher mean score values indicate more severe symptoms.
on.2019.e01272
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
7 https://doi.org/10.1016/j.heliy
2405-8440/ 2019 Published
(http://creativecommons.org/li
Article Nowe01272history of neuroleptic treatment, and baseline social function score was higher in the
incident (48.7) compared to prevalent cases (40.4). Both incident and prevalent cases
were followed for ten years.
There was a progressive increase in the SF-36 social functioning (SF) scores (i.e., the
trend of improvement) during the period, but this was not as marked for physical
functioning (Fig. 2). The level of improvement in social and physical function
was higher in incident than prevalent cases. However, the scores for both were
signiﬁcantly lower than that of the population means for most of the follow-up
period, as shown by the non-overlap of the 95% conﬁdence limits of the mean values
between the study and the general population.
Percentages of follow-up time in reduced functional states are shown in Fig. 3.
Three-quarters of the cohort had reduced functioning for at least two years, and
15e30% for at least six years. A higher percentage of prevalent cases had reduced
functioning (i.e., physical and social functioning lower than the population norm)
for a longer period compared to incident cases. For example, 15% of incident and
30% of prevalent cases had reduced social functioning for at least six years. The cor-
responding ﬁgures for physical function were 11% and 27%, respectively.
The association between the yearly improvement of social and physical functioning,
and course of illness on the one hand and demographic and clinical factors on the
other were evaluated using multivariate random mixed linear model (Table 2). Base-
line social functioning was signiﬁcantly associated with improving trend of social
functioning throughout the follow-up study (P < 0.001). Improvements in social
functioning were signiﬁcantly associated with declining PSR scores (i.e., symptom
severity) throughout the follow-up study in prevalent cases (P < 0.001), but was not
evident in incident cases. Onset age, onset speed, duration of illness at recruitment,Fig. 2. Yearly trend in mean functioning level (%) of people with schizophrenia* compared to the gen-
eral population norm, Butajira, Ethiopia (the ﬁne dotted lines represent 95% conﬁdence limits). * Incident
cases (n ¼ 79) are those with the onset of illness two years or less on entry to the study. The rest were
categorized as prevalent cases (n ¼ 237); Short Form Medical Outcome (SF-36) physical and social func-
tion scores were used as outcome measures. SF-36 score mean values are given on a scale of 1e100.
Higher mean values indicate higher functioning.
on.2019.e01272
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Fig. 3. Length of time in which people with schizophrenia had reduced social and physical functioning*,
Butajira, Ethiopia. * As compared with the population norm. For example: about a third (29%) of the
incident and close to half (43%) of prevalent cases had reduced social functioning for ﬁve years or
more. Incident cases are those with the onset of illness two years or less on entry to the study.
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bacco, and khat1), and medication adherence were not associated with social func-
tioning. Similarly, age, sex, rural residency, education, and marital statuses were
not related to social functioning.
The baseline level of PF scores (Table 3) was signiﬁcantly associated with
improving trend of physical functioning during the follow-up period in both inci-
dent and prevalent cases (P < 0.001). Improvement to physical functioning was
not signiﬁcantly associated with declining PSR scores during the follow-up
period. Age of onset, onset speed, illness duration at recruitment, history of
use of neuroleptic treatment before recruitment, substance use, and medication
adherence were not associated with physical functioning. Age, sex, rural resi-
dence, education, and marital status were not associated with improvement in
physical functioning.4. Discussion
Our results show that physical and social functioning of the study population with
schizophrenia were lower than the population norm for most of the follow-up
time, although functioning improved with time. Declining symptom severity during
the follow-up period were associated with improvements to social functioning when
baseline functioning was controlled for. Demographic or illness characteristics (age
and speed of onset, illness duration, neuroleptic use at entry, substance use, and
medication adherence) were not associated with the long-term trend in functionality
or clinical course.1 Khat is a ﬂowering plant (Catha edulis), the leaves of which are chewed for their stimulant and
appetite-suppressing eﬀect. The leaves contain cathinone, which is an amphetamine-like molecule.
on.2019.e01272
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
Table 2. Factors associated with a yearly trend in improvement of the social functioning of people with schizophrenia followed for an average of 10
years in Butajira, Ethiopia.
Incident Casesa Prevalent Cases All Cases
bb 95% conﬁdence interval P bb 95% conﬁdence interval P bb 95% conﬁdence interval P
Lower Upper Lower Upper Lower Upper
Age Years .05 .2 .1 ns .01 .05 .1 ns .00002 .1 .1 ns
Sex Female 1.2 1.1 3.5 ns .2 1.4 1.0 ns .1 .9 1.2 ns
Male Ref Ref Ref
Residence Urban 1.1 1.0 3.3 ns .1 1.0 1.2 ns .3 .6 1.3 ns
Other Ref Ref Ref
Education Years .03 1.4 1.4 ns .02 .1 .2 ns .1 .1 .2 ns
Other Ref Ref Ref
Marital status Married .003 2.5 2.5 ns .4 1.5 .7 ns .3 1.4 .7 ns
Other Ref Ref Ref
Age of onset Years 1.0 2.1 .2 ns .02 .1 .1 ns .01 .1 .1 ns
Speed of onset Acute 1.1 1.0 3.2 ns .2 .8 1.3 ns .2 .7 1.1 ns
Insidious Ref Ref Ref
Duration of illness at entry Years .1 .7 .5 ns .01 .1 .1 ns .01 .1 .1 ns
Neuroleptic use at entry No 1.8 3.9 .3 ns .5 2.0 1.0 ns .8 2.0 .4 ns
Yes Ref Ref Ref
Substance use No .7 2.8 1.5 ns .04 1.0 1.0 ns .1 .9 .8 ns
Yes Ref Ref Ref
Medication adherence 75% .2 1.8 2.1 ns .8 .2 1.7 ns .7 .2 1.5 ns
>75% Ref Ref Ref
Yearly severity of illness score 1e6 .4 1.1 .2 ns .4 .7 .04 ns .4 .7 .1 ns
Baseline social function score 1e100 .5 .3 .6 <.001 .4 .3 .5 <.001 .5 .4 .5 <.001
Time Years 1.5 .5 2.5 .005 1.2 .6 1.7 <.001 1.3 .8 1.7 <.001
Intercept 1e100 60.0 54.9 65.1 <.001 56.1 53.5 58.6 <.001 56.9 54.6 59.2 <.001
a Incident cases are those with the onset of illness two years or less on recruitment to the study.
b Yearly mean follow-up scores on the Short Form Medical Outcome (SF-36) social function scores were used as outcome measures. Coeﬃcients, B, obtained from a random coeﬃcient model
adjusted for age, sex, baseline SF36 scores, and longitudinal Psychiatric Status Rating (PSR) scores, and follow-up duration. A positive coeﬃcient, B, indicates a trend of improvement in func-
tioning. ns ¼ not signiﬁcant.
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Table 3. Factors associated with a yearly trend in improvement of the physical functioning of people with schizophrenia followed for an average of 10
years in Butajira, Ethiopia.
Incident Casesa Prevalent Cases All Cases
bb 95% conﬁdence interval P bb 95% conﬁdence interval P bb 95% conﬁdence interval P
Lower Upper Lower Upper Lower Upper
Age Years .1 .0 .2 ns .02 .02 .1 ns .03 .01 .1 ns
Sex Female .1 1.4 1.3 ns .8 .03 1.6 ns .6 .1 1.3 ns
Male Ref Ref Ref
Residence Urban .4 1.6 .8 ns .7 1.4 .1 ns .6 1.3 .0 ns
Other Ref Ref Ref
Education Years .01 .2 .1 ns .1 .2 .04 ns .04 .1 .04 ns
Other Ref Ref Ref
Marital status Married .6 .9 2.1 ns .1 .9 .6 ns .02 .7 .7 ns
Other Ref Ref Ref
Age of onset Years .2 .9 .4 ns .1 .1 .01 ns .04 .1 .01 ns
Speed of onset Acute .1 1.3 1.1 ns .3 1.1 .4 ns .3 .9 .3 ns
Insidious Ref Ref Ref
Duration of illness at entry Years .3 .2 .9 ns .03 .01 .1 ns .03 .01 .1 ns
Neuroleptic use at entry No .3 1.6 .9 ns .9 .2 2.0 ns .5 .3 1.4 ns
Yes Ref Ref Ref
Substance use No .5 .8 1.7 ns .1 .6 .8 ns .2 .4 .8 ns
Yes Ref Ref Ref
Medication adherence 75% .6 .5 1.7 ns .1 .7 .6 ns .04 .5 .6 ns
>75% Ref Ref Ref
Yearly severity of illness score 1e6 .1 .4 .3 ns .04 .2 .3 ns .01 .2 .2 ns
Baseline physical function score 1e100 .4 .4 .5 .000 .5 .4 .5 .000 .5 .4 .5 .000
Time Years .02 .7 .7 ns .4 .03 .8 Ns .3 .03 .7 ns
Intercept 1e100 83.6 80.2 86.9 .000 75.7 73.7 77.7 73.3 77.4 75.6 79.1 .000
a Incident cases are those with the onset of illness two years or less on recruitment to the study.
b Yearly follow-up scores on the Short Form Medical Outcome (SF-36) physical function scores were used as outcome measures. Coeﬃcients, B, obtained from a random coeﬃcient model adjusted
for age, sex, baseline SF36 scores, and longitudinal Psychiatric Status Rating (PSR) scores, and follow-up duration. A positive coeﬃcient, B, indicates a trend of improvement in functioning. ns ¼
not signiﬁcant.
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avoid methodological pitfalls. We included all people with schizophrenia from a
deﬁned community instead of institutional-based enrolment, and over 85% of the
people with schizophrenia were neuroleptically naïve at baseline. We stratiﬁed inci-
dent in addition to prevalent cases and controlled for duration of illness in a multi-
variate model to limit selection bias (Revier et al., 2015). We used accepted
diagnostic classiﬁcation schemes and data collection tools that have been evaluated
for reliability (Alem et al., 2004; Kebede et al., 2004b; Fekadu et al., 2000; Rashid
et al., 1996). Clinical diagnoses and course of illness were assessed longitudinally
using standardized methods. We were able to compare functional outcomes of the
study population to that of the general population and used suitable multivariate
models to allot address possible confounders when evaluating predictors of func-
tional and clinical outcomes.
Due to schizophrenia’s ability to be disabling, baseline functioning levels are ex-
pected to be lower in those with schizophrenia compared to the general population.
Although this gap diminished, it persisted after the follow up, indicating high levels
of residual disability due to the illness. We have shown that a substantial percentage
of people with schizophrenia had continued to be in a state of reduced functioning
during follow-up. Thus, although on average improvement was seen, a signiﬁcant
percentage of cases had a chronic unrelenting course of illness as was described
in the literature (J€a€askel€ainen et al., 2013; Newman et al., 2012; Haro et al., 2008;
Cohen et al., 2008; Patel et al., 2006). We are not aware of other studies of schizo-
phrenia that had attempted a comparison of functioning in cases and the general
population.
Our ﬁnding of low levels of physical and social functioning at baseline was to be
expected since most of the people with schizophrenia had no history of neuroleptic
use before joining the study. In addition, improvement in social functioning during
follow-up was expected as all cases were treated by typical neuroleptics. Other
studies have also reported functional recovery during the ﬁrst ﬁve years after recov-
ery (Robinson et al., 2004). On the other hand, it is possible that our ﬁnding may
under-estimate the actual functioning level of the people with schizophrenia. This
is because long-standing cases may express relative satisfaction with their condition
due to adaptation to their condition over time and because they usually compare
themselves to their peer group with similar impairments instead of the general pop-
ulation (Priebe, 2007; Habtamu et al., 2017).
Longitudinal symptom severity level was associated with social functioning in our
study. Several studies reviewed by Jarcaz et al., (2015) have also shown similar
results. When symptom severity is controlled for in the mixed random model,
physical and social functioning were not associated with socio-demographic sep-
arations or characteristics. This is in accord with our earlier report on the shorton.2019.e01272
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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However, this is not in accord with follow-up studies conducted in developed,
as well as developing countries (Rangaswamy and Greeshma, 2012; Bromet
et al., 1995; Jablensky et al., 1992). Systematic reviews (van der Werf et al.,
2014) have shown gender as an important predictor at diﬀerent stages of life,
although our study did not show this. This could be diﬀerences in methods be-
tween our and other studies. Very few of such studies adjusted for covariates using
appropriate multivariate models for repeated measurements as we did. The associ-
ations observed in those other studies were thus not shown to be independent of
each other or to other relevant clinical factors, particularly diﬀerences in baseline
functioning and longitudinal illness severity.
Both duration of illness and neuroleptic naivety were found to not be associated
with trends of physical and social functioning in the current study. Illness dura-
tion throughout the study might correspond to the duration of untreated psychoses
(DUP); the majority of cases had no history of treatment with a neuroleptic medi-
cation at baseline. DUP showed an association with poor outcomes in some
studies in both developed and developing countries (Penttila et al., 2014;
Norman and Malla, 2001). However, its signiﬁcance has been disputed as it
may be the result of confounding (Verdoux et al., 2001). Substance use was
not signiﬁcantly associated with functioning in our study, although some studies
had shown such an association as reviewed by Holla and Thirthalli (2015). How-
ever, the reviewers had stated that substance use and outcome in schizophrenia
had not been well studied. Treatment adherence was also not associated with
functionality. Our ﬁndings of non-signiﬁcant association between substance use
and treatment adherence with functionality could be due to type II error as the
size of group was relatively small.
The study did have limitations. The possibility of errors due to misclassiﬁcation
of age as a proportion of participants could not state their actual age, which neces-
sitated using major historical events in an eﬀort to estimate age. Thus, any accu-
racy regarding related variables including age of onset and illness duration may
be aﬀected. The LIFE Chart and PSR scores were used to measure clinical
severity. It is not clear how this method compares with standard scales for psy-
chopathology such as PANSS (Suzuki, 2011). Our assessments of functional
outcome were completed cross-sectionally and annually. It was assumed assess-
ments would reﬂect an accurate pattern of outcomes throughout the 12 months
before the assessment. While this is common practice, we cannot ascertain
whether people with schizophrenia had a stable course of illness throughout the
duration of the intervening period between annual assessments. Symptomatic
and functionality assessment were based on information obtained from both the
patients and care-givers.on.2019.e01272
by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
censes/by-nc-nd/4.0/).
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Article Nowe01272In conclusion, our study shows a signiﬁcant gap in physical and social functioning
between the study and the general population that persisted with the follow-up, albeit
with the diminishing of the gap with time. Baseline functioning levels and course of
illness were associated with long-term functioning. When adjustments were made,
socio-demographics and additional clinical factors were not associated with trends
in physical and social functioning. Long-term follow-up studies of 20e30 years
are rare in developing countries and have not been conducted throughout sub-
Saharan Africa. Further, follow up of the people with schizophrenia in Butajira is
recommended to describe longer-term illness course and functional outcomes.Declarations
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